Excited to announce our investment in Arpeggio Bio, which engineers drugs to change the transcriptome, with the goal of making safer and more effective medicine. The $17M series A is being led by Builders VC and includes also existing investors Khosla Ventures, TechU, FundersClub and new investors Tencent, Formic, ATEM, BoxOne and Matt De Silva. Tau Ventures is an AI-first fund in Silicon Valley investing primarily in seed and we occasionally take earlier or later bets when we see immense promise. We are also investing in US / Canada but in exceptional cases will consider a deal outside. Arpeggio was…...
Why We Invested in Arpeggio Bio — Making Safer And More Effective Medications
1 min read